BioLife Solutions, Inc. (BLFS) News
Track canonical SquawkNews coverage tagged to BLFS, BioLife Solutions, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Repligen to acquire BioLife Solutions for $11.25 cash plus stock
BioLife Solutions agreed to be acquired by Repligen for $11.25 cash and 0.1442 shares of Repligen stock per BioLife share.
MNA | Sep 09, 2026, 09:24 PM UTC
L
BLFS Downgrade from Overweight to Equal Weight at Stephens
BLFS Downgrade from Overweight to Equal Weight at Stephens
EQUITY | Jul 27, 2026, 12:07 PM UTC
L
BLFS Downgrade from Buy to Hold W/$31.00 PT (from $33.00) at TD Cowen
BLFS Downgrade from Buy to Hold W/$31.00 PT (from $33.00) at TD Cowen
EQUITY | Jul 23, 2026, 11:55 AM UTC
L
BLFS downgraded from Buy to Hold W/ $21 PT (from $33) @ TDCowen
BLFS downgraded from Buy to Hold W/ $21 PT (from $33) @ TDCowen
EQUITY | Jul 23, 2026, 10:53 AM UTC
L
RGEN said it would buy Biolife Solutions (BLFS) in a cash-and-stock deal valued at about $1.5B, to expand its presence in the fast-growing c
RGEN said it would buy Biolife Solutions (BLFS) in a cash-and-stock deal valued at about $1.5B, to expand its presence in the fast-growing cell therapy market; Biolife shareholders will receive $11.25 in cash and 0.1442
EQUITY | Jul 22, 2026, 10:19 AM UTC